TMCnet News

Clene to Present at Upcoming May Conferences
[May 14, 2024]

Clene to Present at Upcoming May Conferences


SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May.

Mizuho Neuroscience Summit 2024
Dates: May 20-21, 2024
Location: Boston Harbor Hotel, Boston, MA
Format: Panel Presentations and 1x1 meetings

Benchmark 2024 Healthcare House Call Virtual Conference
Dates: May 21-22, 2024
Location: Virtual
Format: 1x1 meetings

Virtual A.G.P. Healthcare Conference
Date: May 22, 2024
Location: Virtual
Format: 1x1 meetings

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.



Contacts:

Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310
Investor Contact
Kevin Gardner
LifeSci Advisors
[email protected]
617-283-2856



Primary Logo


[ Back To TMCnet.com's Homepage ]